Registry update — unassessed
METformin And Longevity (METAL): A Window of Opportunity Study Investigating Biological Effects of Metformin in Localised Prostate Cancer
Trial registry update: UNKNOWN. No results reported in the supplied registry record.
RCTMinor significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Jul 30, 2015 · Discovered: Sep 15, 2026 · Assessed: — · Historical research backfill
What it does not prove
- No findings are reported, so no clinical outcomes regarding metformin's effectiveness in prostate cancer can be assessed from this source
- The window of opportunity design (short-term intervention before standard treatment) limits generalizability to long-term use or effects on advanced disease
- Biological mechanism findings, if any exist, were not described in the provided abstract
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Patients with localised prostate cancer
- Primary outcome
- Biological mechanism of metformin in prostate cancer (inferred from title; specific biomarkers not specified in abstract)
- Effect size
- —
- Significance
- Not reported
- Journal
- Guy's and St Thomas' NHS Foundation Trust
- Published
- Jul 30, 2015
Sources
Primary source
- Guy's and St Thomas' NHS Foundation Trust ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
This is a randomized, placebo-controlled, double-blind, window of opportunity study investigating the biological mechanism of metformin in prostate cancer.
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.